Based on the patient's medical report, I have identified a few clinical trials that may be relevant. However, it's essential to note that the patient's history of brain metastases and liver metastasis may affect eligibility for certain clinical trials.

1. **NCT05950945**: This Phase 3b study is investigating Trastuzumab Deruxtecan (T-DXd) in subjects with unresectable and/or metastatic HER2-low or HER2 IHC 0 breast cancer. Although the patient's HER2 status is positive, the trial allows for patients with HER2 IHC 2+/ISH- status, which might be relevant. The patient's prior treatment with trastuzumab and pertuzumab may also be considered. The expected prognosis outcome is the time from the start of T-DXd to initiation of subsequent anticancer treatment (TTNT). Possible risks associated with this trial include cardiovascular events, interstitial lung disease, and hypersensitivity reactions.

Contact Information:
(US Sites) Daiichi Sankyo Contact for Clinical Trial Information - CONTACT
Phone: 908-992-6400, Email: CTRinfo@dsi.com

(Asia Sites) Daiichi Sankyo Contact for Clinical Trial Information - CONTACT
Phone: +81-3-6225-1111 (M-F 9-5 JST), Email: dsclinicaltrial@daiichisankyo.co.jp

2. **NCT05292742**: This randomized, open-label, multicenter study is comparing continuation of original targeted therapy with trastuzumab combined with pyrotinib and capecitabine as postoperative adjuvant therapy in non-pCR patients with HER2-positive early breast cancer. Although the patient has metastatic disease, the trial's focus on HER2-positive breast cancer and the combination of trastuzumab with other therapies might be relevant. The expected prognosis outcome is the 3-year invasive disease-free survival (iDFS) rate. Possible risks associated with this trial include cardiac toxicity, hematologic toxicity, and hypersensitivity reactions.

Contact Information:
Chuan Wang - CONTACT
Phone: 13515020716, Email: chuanwang68@qq.com
Silu Wang - CONTACT
Phone: 18559171530, Email: wangsiluaaron@163.com

3. **NCT05891561**: This open-label, single-arm study is investigating short-course trastuzumab, pertuzumab combined with taxanes in the adjuvant treatment of early HER2-positive breast cancer. Although the patient has metastatic disease, the trial's focus on HER2-positive breast cancer and the combination of trastuzumab with other therapies might be relevant. The expected prognosis outcome is the disease-free survival (DFS) rate. Possible risks associated with this trial include cardiac toxicity, hematologic toxicity, and hypersensitivity reactions.

Contact Information:
Xiaosong Chen - CONTACT
Phone: +8621-64370045*602102, Email: chenxiaosong0156@hotmail.com
Yiwei Tong - CONTACT
Phone: +8621-64370045*602107, Email: ash_yiwei@sjtu.edu.cn

It's essential to note that these trials may have specific eligibility criteria, and the patient's medical history and current disease status should be carefully evaluated to determine the best course of treatment. The patient's oncology team should discuss the potential benefits and risks of each trial and determine the most suitable option.